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Introduction
Secondary label-conjugated and non-conjugated detection antibodies are frequently used in a wide range of research applications. However, they are often affinity-isolated, polyclonal reagents that may lack the highest standard of antibody validation. The antibodies characterised in this study are a polyclonal anti-chicken IgY antibody produced in rabbit (31104, Thermo Fisher) and a polyclonal goat anti-rabbit IgG antibody conjugated with alkaline phosphatase (AP) (A3687, Sigma-Aldrich). Although the use of the rabbit anti-IgY antibody in the literature is limited, the goat anti-rabbit IgG AP was extensively utilised in research for over 15 years 1, 2 .
The research conducted in this laboratory examines complex antibody repertoires in humans and animals by means of protein arrays. Protein arrays are frequently used to profile antibody binding to human proteins in autoimmune disease 3 , cancer 4 and in healthy individuals 5 . Other protein array applications include recombinant 6 and hybridoma-derived 7 antibody characterisation studies. This article investigates the cross-reactivity of a rabbit anti-chicken IgY and an alkaline phosphatase-conjugated goat anti-rabbit IgG, which were used for the profiling of IgY antibody responses to human antigens in chickens immunised with human cancer cells. The protein array technology applied here, developed by Büssow and colleagues 8 , is comprised of a fully annotated set of 7,390 distinct human proteins, in its current version, that may serve as potential antigens. The aim of this study is to define a cross-reactivity reference list for the two described secondary antibodies, which can then be used to eliminate non-specific binders from ongoing chicken IgY profiling studies. Furthermore, publication of the cross-reactivity reference list may support other researchers using these antibodies in the evaluation of their experiments.
Materials and methods

Antibody details
Rabbit anti-chicken IgY (H+L) secondary antibody (Thermo Fisher Scientific, Product code 31104, Lot code PK19380211) is a polyclonal antibody that targets the variable heavy and light chains of chicken IgY immunoglobulins ( Table 1 ). The antibody was isolated from the serum of the antigen-immunised rabbit through immunoaffinity chromatography using antigen coupled to agarose beads.
The antibody was added to the protein array at a 1/1,000 dilution in 2% (w/v) bovine serum albumin (BSA, Sigma-Aldrich, A2153) in tris-buffered saline (TBS, Trizma ® Base, Sigma-Aldrich, T6066 and sodium chloride, Fisher Scientific, S/3160/68) with 0.1%, v/v, Tween 20 (Sigma-Aldrich, P1379).
Alkaline phosphatase-conjugated goat anti-rabbit IgG (whole molecule) (Sigma-Aldrich, Product code A3687, Lot code SLBJ6146V) is a polyclonal antibody that targets all rabbit IgGs ( Table 1) . The antibody was isolated through immunospecific purification of antisera from a rabbit IgG-immunised goat. Following isolation, the anti-rabbit IgG was conjugated to alkaline phosphatase using glutaraldehyde-based cross-linkage. The antibody was added to the protein array at a 1/1,000 dilution in 2% (w/v) BSA in tris-buffered saline (TBS) with 0.1%, v/v, Tween 20.
Protein arrays
Unipex protein arrays were obtained from Source Bioscience Life Sciences (Nottingham, UK). The Unipex arrays comprise of 15,300 fully annotated E. coli clones expressing a total of 7,390 distinct in-frame ORF human recombinant proteins. The Unipex proteins are immobilized under denaturing conditions directly on the PVDF membrane surfaces exposing linear sequence epitopes ideally suited for epitope mapping, antibody profiling and antibody cross-reactivity analyses. The details of protein arrays utilised in this study are provided in Table 2 . For general information on Unipex protein arrays please refer to: (http://www.lifesciences. sourcebioscience.com/media/290406/sbs_ig_manual_proteinar-ray_v1.pdf).
Cross-reactivity assessment
Antibody cross-reactivity was assessed using Unipex protein arrays. The detailed experimental protocol is provided in Table 3 . Briefly, secondary rabbit anti-chicken IgY and goat anti-rabbit IgG AP were validated in preparation for a chicken IgY antibody profiling experiment of a chicken immunised with human cancer cells. Protein arrays were probed with secondary antibodies in the absence of IgY-containing chicken serum, as described in Table 3 . Signal generation for array-bound secondary antibodies was obtained using AttoPhos AP fluorescent substrate system (Promega, S1001) 
Results
Probing protein arrays with antibodies enables the assessment of specificity and cross-reactivity on large numbers of potential antigens in parallel. Here we investigated the cross-reactivity of secondary anti-chicken IgY from rabbit and anti-rabbit IgG AP from goat using human protein arrays in the absence of chicken serum. The analysis revealed antibody binding to human proteins in the absence of chicken serum and hence chicken IgY immunoglobulins. The identified positive signals varied in strength, as shown in Figure 1 , with intensity 3 being the strongest and 1 the weakest. The difference in signal intensities may relate to varying protein quantities on the array and differences in antibody affinities to corresponding proteins. A total of 63 binding events were visible on the protein arrays, of which 61 corresponded to unique proteins ( Table 4 ). Five of the identified signals were scored as intensity 3, twelve signals were scored as intensity 2 and remainder were scored as intensity 1. The original protein array images are shown in Figure S1 and Figure S2 (Supplementary material) and protein array images with highlighted positive signals, which correspond the cross-reactive proteins listed in Table 4 , are shown in Figure S3 and Figure S4 (Supplementary material).
The investigated antibodies were found to bind to a wide range of human proteins (Table 4 ). However, it is worth noting that a total of six identified binding events correlated to human immunoglobulin proteins, with four scored at the highest intensity (Intensity 3). Such cross-reactivity is not surprising considering the antibodies are polyclonal and the immunogens of both hosts were immunoglobulins. In addition, the data sheet provided with the anti-chicken IgY antibody produced in rabbit (31104, Thermo Fisher) has specified that this antibody may cross-react with immunoglobulins from other species. The data sheet for the goat anti-rabbit IgG AP antibody (A3687, Sigma-Aldrich) has specified binding to all rabbit immunoglobulins. 
Conclusion
This work illustrates the cross-reactivity of an antibody-based detection system for IgY binding. The polyclonal anti-IgY rabbit antibody in combination with an anti-rabbit IgG alkaline phosphatase-conjugated antibody was shown to bind to 61 human proteins present on Unipex protein arrays comprising of 7,390 human proteins. Characterisation of this cross-reactivity provides a 'false-positive' database for future chicken antisera characterisation on protein array systems not limited to the Unipex protein array used here. These results, in combination with 'false-positives' from earlier research investigating antibody cross-reactivity by this group 9 and others 10 may provide valuable information for future protein array-based experiments. Reference lists provided by such experiments would be further strengthened by arrays that include additional portions of the human proteome and/or post-translational modifications. Using antibodies that have been extensively characterised on protein arrays will reduce the risk of identifying irrelevant cross-reactive secondary antibody binding to the array as a host-antigen response.
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which are homologous to the original immunogens. Despite the identified non-specific binding, the tested antibodies are suitable for use in protein array experiments as the cross-reactive binding partners can be readily excluded from further analysis. As both antibodies were used as a pair in this study, the possibility to deduce the exact cross-reactivity profile for each individual antibody may be limited. However, the cross-reactivity reference list provided in this paper can be further utilised to validate research using those antibodies in applications other than protein arrays.
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or first antibody on a protein array and with just the detection antibodies makes perfectly sense to control for unspecific binding. The title of the paper is appropriate, the abstract gives enough information on the setting. The background information about the antibodies is described in enough detail. However, the narrow focus of the paper and a number of technical issues limit the quality of the paper and its utility for the readership.
Major issues
The experiment was performed only once. Consequently, the reliability of the results will be limited.
Only one specific combination of a protein macroarray with two consecutive detection antibodies was analyzed. It remains unclear, whether the results obtained would apply to other lots of the antibodies or whether they are specific for a certain preparation, limiting the benefit of this protein list as a reference database and also limiting the replication of results by other groups.
The authors suggest that their results may also apply to other protein array systems. This claim needs substantiation, especially in the case of proteins derived from high-throughput cloning E.coli that do not show authentic posttranslational modification patterns and often contain extra amino acid sequences that may cause unspecific binding. The paper discusses cross-reactivity with human Ig genes. A sequence analysis of the other cross-reactive proteins with IgY and rabbit Ig sequences may provide evidence for the mechanisms behind this phenomenon, expanding scope and depth of this so far rather descriptive study.
Minor issues
Antibody concentrations should be given explicitly, e.g. as µg/ml rather than as dilutions.
The procedure of signal quantification and scoring needs to be described in more detail. The description states "Positive signals were localized according to the manufacturer's protocol" -what exactly was done to identify positive signals? The pictures provided show varying background intensities as well as a number of very dark spots that do not appear in the analysis. Which algorithm was used to include or exclude signals? How were the different signal intensities attributed to the score values 1, 2 and 3?
It would be interesting to know why this specific combination of two detection antibodies was used here: a polyclonal anti-chicken IgY antibody produced in rabbit and then a polyclonal goat anti-rabbit IgG antibody conjugated with alkaline phosphatase. Was there no conjugated anti-chicken antibody available? Every additional antibody will add to the number of unspecific reactions, so using just one instead of two may help reduce background.
The abstract does not provide a conclusion on whether the antibodies should be used in a particular setting (see Article Guidelines For Antibody Validation Articles).
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